Management of pregnant chronic myeloid leukemia patients

References

• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myeloid leukaemia in mice by the p210 bcr-abl gene of the Philadelphia chromosome. Science. 1990;247:824–830.
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306:239–242.
   PubMed Web of Science ®Google Scholar
• Deininger MWN, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood. 1997;90(9):3691–3698.
   PubMed Web of Science ®Google Scholar
• Marley SB, Deininger MWN, Davidson RJ, et al. The tyrosine kinase inhibitor STI571, like interpheron-a preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol. 2000;28:551–557.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990–998.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL1 leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380–394.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Hehlmann R. Trial of STI571 before proceeding to allografting for CML? Leukemia. 2000;14:1560–1562.
   PubMed Web of Science ®Google Scholar
• Deininger MW, O’Brien S, Guilhot F, et al. International randomized study of interferon vs ST1571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly-diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract). Blood. 2009;114(22):1126.
   Web of Science ®Google Scholar
• Talpaz DM. STI-571 in chronic myelogenous leukaemia. Br J Haematol. 2002;119:15–24.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Breccia M, Latagliata R. Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML). BioDrugs. 2014 Feb;28(1):17–26. Erratum in: BioDrugs. 2014 Jun;28(3):325.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10;27(35):6041–6051.
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015 Jun;29(6):1336–1343.
   PubMed Web of Science ®Google Scholar
• Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. India J Med Paediatr Oncol. 2013 Jul–Sep;34(3):154–158.
   PubMedGoogle Scholar
• Şahin F, Saydam G, Cömert M, et al. Turkish chronic myeloid leukemia study: retrospective sectional analysis of CML patients. Turk J Haematol. 2013 Dec;30(4):351–358.
   PubMed Web of Science ®Google Scholar
• Nurmio M, Toppari J, Zaman F, et al. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl. 2007;30(4):366–376.
   PubMedGoogle Scholar
• He K, Lago MW, Iyer RA, et al. Lacteal secretion, foetal and maternal tissue distribution of dasatinib in rats. Drug Metabol Disp. 2008;26(12):2564–2570.
   Web of Science ®Google Scholar
• Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40(2suppl3):21–25.
   PubMed Web of Science ®Google Scholar
• Breccia M, Cannella L, Montefusco E, et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res. 2008;32(3):519–520.
   PubMed Web of Science ®Google Scholar
• Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol. 2007;137(4):374–375.
   PubMed Web of Science ®Google Scholar
• Ault P, Kantarjian H, O’Brien S, et al. Pregnancy among patients with CML treated with imatinib. JCO. 2006;24:1204–1208.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Scortechini AR, Gugliotta G, et al. Gimema registry of conception/pregnancy in adult patients diagnosed with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Blood. 2014;124:1806. abstract
   Web of Science ®Google Scholar
• Iqbal J, Ali Z, Khan AU, et al. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma. 2014 Sep;55(9):2109–2113.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Abruzzese E, Chelysheva E., et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015 Dec;90(12):1111–1115.
   PubMed Web of Science ®Google Scholar
• Gentile M, Guido M, Lucia E, et al. Favourable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib. Leuk Lymphoma. 2014 Mar;55(3):709–710. Epub 2013 Jul 29. doi:10.3109/10428194.2013.811240..
   PubMed Web of Science ®Google Scholar
• Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505–5508.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Trawinska MM, Perrotti AP, et al., Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014Apr7;6(1):e2014028. eCollection 2014. Review. PubMed PMID: 24804001; PubMed Central PMCID: PMC4010610. Doi:10.4084/MJHID.2014.028.
   PubMedGoogle Scholar
• Laferla JJ. Spontaneous abortion. Clin Obstet Gynaecol. 1986;13:105–114.
   PubMed Web of Science ®Google Scholar
• Alizadeh H, Jaafar H, Rajnics P, et al. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leuk Res. 2015 Jan;39(1):47–51.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Dasgupta S, Kanti Ray U, et al. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy. Ir J Med Sci. 2015 Mar;184(1):183–188.
   PubMed Web of Science ®Google Scholar
• Webb MJ, Jafta D. Imatinib use in pregnancy. Turk J Haematol. 2012 Dec;29(4):405–408.
   PubMed Web of Science ®Google Scholar
• Etienne G, Milpied B, Réa D, et al. French intergroup of CML (Fi-LMC group). Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group). Bull Cancer. 2010 Aug;97(8):997–1009.
   PubMed Web of Science ®Google Scholar
• Conchon M, Sanabani SS, Bendit I, et al. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol. 2009;2:42.
   PubMed Web of Science ®Google Scholar
• Alizadeh H, Jaafar H, Kajtár B. Outcome of 3 pregnancies in a patient with chronic myeloid leukemia who received 3 types of tyrosine kinase inhibitors each in different pregnancy: follow-up of the case with a review of published reports. Ann Saudi Med. 2015 Nov–Dec;35(6):468–471.
   PubMed Web of Science ®Google Scholar
• Santorsola D, Abruzzese E. Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib: a case report and a review. Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015020. eCollection 2015. doi:10.4084/MJHID.2015.020.
   Google Scholar
• Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anticancer Drugs. 2012 Aug;23(7):754–757.
   PubMed Web of Science ®Google Scholar
• Kroll T, Ames MB, Pruett JA, et al. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma. 2010;51(9):1751–1753.
   PubMed Web of Science ®Google Scholar
• Conchon M, Sanabani SS, Serpa M, et al. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol. 2010;2010:136252.
   PubMedGoogle Scholar
• Bayraktar S, Morency B, Escalon MP Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester. BMJ Case RepOnline Publ, 2010 Oct 21. doi:10.1136/bcr.05.2010.2975.
   Google Scholar
• Christopoulos C, Dimakopoulou V, Rotas E Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med. 2008;358(10):1079–1080.
   PubMed Web of Science ®Google Scholar
• Zamah AM, Mauro MJ, Druker BJ, et al. Will imatinib compromise reproductive capacity? Oncologist. 2011;16(10):1422–1427.
   PubMed Web of Science ®Google Scholar
• Apperly J. Issues of imatinib and pregnancy outcome. J Natl Compr Cancer Netw. 2009;7(10):1–9.
   Web of Science ®Google Scholar
• Apperly J. CML in pregnancy and childhood. Best practice Res Clin Hematol. 2009;22(3):455–474.
   PubMed Web of Science ®Google Scholar
• Choudhary DR, Mishra P, Kumar R, et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Onclology. 2006;17(1):178–179.
   PubMed Web of Science ®Google Scholar
• Sheehy WT. An evaluation of the effect of pregnancy on chronic granulocytic leukaemia. Am J Obstet Gynecol. 1958;75:788.
   PubMed Web of Science ®Google Scholar
• Jovelet C, Seck A, Mir O, et al. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Ann Oncol. 2015 Jul;26(7):1500–1504.
   PubMed Web of Science ®Google Scholar
• Russel MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentration in maternal blood, umbelical cord blood, placenta and breast milk. J Perinatology. 2007;27:241–243.
   PubMed Web of Science ®Google Scholar
• Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet. 2009;280(2):169–175.
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Minakami H, Koshizuka S, et al., Administration of interferon-α during pregnancy: effect on fetus. J Perinat Med. 2000;28:372–376. 36
   PubMed Web of Science ®Google Scholar
• Vantroyen B, Vanstraelen D. Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha 2a and no treatment. Comprehensive Analysis Literature Acta Hematol. 2002;107:158–169.
   PubMed Web of Science ®Google Scholar
• Dowding C, Gordon M, Guo AP, et al. Potential mechanisms of action of interferon-α in CML. Leuk Lymphoma. 1993;11(Suppl 1):185–191.
   PubMed Web of Science ®Google Scholar
• Roth MS, Foon KA. Alpha interferon in the treatment of hematologic malignancies. Am J Med. 1986;81(5):871–882.
   PubMed Web of Science ®Google Scholar
• Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol. 2015 Apr;94(Suppl 2):S167–S176.
   PubMed Web of Science ®Google Scholar
• Thauvin Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia. 2001;15:1309–1311. 41
   PubMed Web of Science ®Google Scholar
• Fadilah SA, Ahmad-Zailani H, Soon-Keng C, et al. Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia. 2002;16:1202–1203.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–430.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522.
   PubMed Web of Science ®Google Scholar
• Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015 Oct;90(10):910–914.
   PubMed Web of Science ®Google Scholar
• Zhou L, You JH, Wu W, et al. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res. 2013 Oct;37(10):1216–1221.
   PubMed Web of Science ®Google Scholar
• Shapira T, Pereg D, Lishner M. How I treat acute and chronic leukemia in pregnancy. Blood Rev. 2008 Sep;22(5):247–259.
   PubMed Web of Science ®Google Scholar
• Kumar S, Apostolova M, Woolley PV. A case of chronic myelogenous leukemia in pregnancy characterized by a complex translocation t(9;22;11)(q34;q11.2;q13). Hematol Rep. 2011;3(e27):86–90.
   Google Scholar
• Bhandari A, Rolen K, Shah BK. Management of chronic myelogenous leukemia in pregnancy. Anticancer Res. 2015 Jan;35(1):1–11.
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Apperley JF. How I treat leukemia during pregnancy. Blood. 2014 Feb 13;123(7):974–984.
   PubMed Web of Science ®Google Scholar
• Kronenberger R, Schleyer E, Bornhauser M, et al. Imatinib in breast milk. Ann Hematol. 2009;88:1265–1266.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini CB, Tornaghi L, Marangon E, et al. Imatinib concentrations in human milk. Blood 2007;Feb 15 109(4):1790. PMID: 17284536.
   PubMed Web of Science ®Google Scholar
• Chelysheva E, Turkina A, Polushkina E, et al. Introduction of a treatment approach for chronic myeloid leukemia and pregnancy considering leukemic burden and pregnancy terms. Blood. 2015 December 3;126(23):5144. abstract.
   Web of Science ®Google Scholar